MLICM
VRDN icon

Metropolitan Life Insurance Company (MetLife)’s Viridian Therapeutics VRDN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,632
Closed -$46.1K – 2055
2024
Q1 		$46.1K Sell
2,632
-53
-2% -$1.03K ﹤0.01% 1447
2023
Q4 		$58.5K Hold
2,685
– – ﹤0.01% 1360
2023
Q3 		$41.2K Buy
2,685
+377
+16% +$7.19K ﹤0.01% 1515
2023
Q2 		$54.9K Buy
2,308
+261
+13% +$6.7K ﹤0.01% 1367
2023
Q1 		$52.1K Sell
2,047
-293
-13% -$9.39K ﹤0.01% 1365
2022
Q4 		$68.4K Buy
2,340
+748
+47% +$17.2K ﹤0.01% 1281
2022
Q3 		$32.7K Hold
1,592
– – ﹤0.01% 1743
2022
Q2 		$18.4K Buy
+1,592
New +$21.4K ﹤0.01% 2080

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VRDN Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Viridian Therapeutics (VRDN) in Q2 2024, closing a stake of 2,632 shares — an estimated $46.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VRDN in Q2 2022 and held it in 8 quarters. The position peaked at $68.4K in Q4 2022. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Viridian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,632 Viridian Therapeutics shares in Q2 2024, an estimated $46.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Viridian Therapeutics in Q2 2022 and held it in 8 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Viridian Therapeutics position peaked at $68.4K in Q4 2022.
  • 138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.